For full functionality of this site it is necessary to enable JavaScript. Here are the instructions how to enable JavaScript in your web browser.

Scientific Program

FP347

4290MW

Dr.TARNOOM ABDULREHMAN ATHANI
Membership No Author Name Email Mobile
4290MW Dr.TARNOOM ABDULREHMAN ATHANI tarnoom.athani@gmail.com 9632661975
Orbit & Oculoplasty

Efficacy of IV methylprednisolone and Mycophenolate in active moderate to severe thyroid eye disease

Purpose
To evaluate outcomes of IV methylprednisolone pulse therapy with mycophenolate in active, moderate-to-severe thyroid eye disease [TED].
Methods
32 patients [52 eyes] with active TED [CAS ≥3] and moderate-to-severe disease per 2021 EUGOGO criteria received IVMP 4.5g cumulative dose. Mycophenolate 1g/day for 24 weeks was added in 22 patients. Thyroid function tests, CAS, Hertel exophthalmometry, BCVA, color vision, extraocular motility, diplopia assessment, and orbital imaging [CT/MRI]. 6-month outcomes: CAS, proptosis, diplopia, BCVA, and adverse events.
Results
Mean CAS decreased from 6.9±1.3 to 0.8±0.7. Remission in 28 patients [87.5%]. Proptosis reduced ≥2 mm in 35/52 eyes [67.3%]. Diplopia resolved in 12/24 patients [50%]. Extraocular motility improved in 19/32 patients [59.4%]. No serious adverse events.
Conclusion
IVMP with mycophenolate is safe and effective for active moderate-to-severe TED, achieving disease remission and significant functional and cosmetic improvement.

Membership No Author Name Email Mobile
1679 Dr.Anand G Gannur anandggannur@yahoo.com 9481630838
1680 Dr.Madhu madhu087@gmail.com 9844860275
4646 Dr.Shylaja P Biradar shylajag8@gmail.com 9894944021